Mounjaro (Tirzepatide) SURPASS-2 Highlights infographic Video

Shed light on the SURPASS 2 trail, A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes (SURPASS-2)





Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: [email protected]
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

Please go to PDF Material for prescribing information


PP-TR-SA-0054